Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First DataBank FTC Divestiture Order Allows Joint Venture After 3 Years

Executive Summary

Hearst subsidiary First DataBank could form a joint venture with Facts and Comparisons after selling the firm its Medi-Span Master Drug Data Base under a proposed settlement with the Federal Trade Commission

You may also be interested in...



FTC disgorgement

Federal Trade Commission is seeking comments on the use of disgorgement as a remedy in antitrust cases. The commission is interested in input on whether seeking disgorgement could delay other remedial actions. The issue arose in FTC's handling of First DataBank's acquisition of Medi-Span (1"The Pink Sheet" Dec. 3, 2001, p. 19)...

FTC disgorgement

Federal Trade Commission is seeking comments on the use of disgorgement as a remedy in antitrust cases. The commission is interested in input on whether seeking disgorgement could delay other remedial actions. The issue arose in FTC's handling of First DataBank's acquisition of Medi-Span (1"The Pink Sheet" Dec. 3, 2001, p. 19)...

First DataBank Must Create Integratable Data Files Competitor, FTC Says

First DataBank would be required to set up a competitor in the integratable drug data file market under an April 4 FTC complaint regarding the 1998 acquisition of Medi-Span by Hearst, which also owns First DataBank.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS038927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel